Introduction to Refractory CNS Tuberculosis

Tuberculous meningoencephalitis (TBM) remains a significant cause of morbidity and mortality in pediatric populations globally. While standard antitubercular therapy (ATT) is effective for most, some patients develop severe complications or paradoxical reactions. A recent case report highlights the successful use of infliximab for tuberculous meningoencephalitis in a 5-year-old child who could not tolerate standard treatment. This case provides hope for managing refractory central nervous system tuberculosis when conventional methods fail.

Clinical Challenges and Treatment Barriers

The patient initially presented with classic symptoms of TBM and began standard ATT. However, the child quickly developed severe drug-induced hepatitis. Consequently, clinicians had to discontinue the primary medications. The medical team transitioned the patient to second-line drugs combined with high-dose corticosteroids. Despite these interventions, the disease progressed significantly, showing both clinical deterioration and worsening radiologic markers. This scenario is particularly challenging as the immune response itself often drives the damage in CNS tuberculosis.

The Role of Infliximab for Tuberculous Meningoencephalitis

Tumor Necrosis Factor-alpha (TNF-α) plays a dual role in tuberculosis. While it is necessary for granuloma formation, excessive TNF-α levels can lead to devastating neuroinflammation. In this refractory case, clinicians introduced infliximab, a potent TNF-α inhibitor. This targeted biological therapy aimed to dampen the hyper-inflammatory state that steroids could not control. Specifically, the introduction of infliximab resulted in substantial clinical and radiologic improvement. The child showed a remarkable recovery, suggesting that TNF-α blockade can serve as a powerful salvage therapy in pediatric neurotuberculosis.

Mechanisms of Salvage Therapy

Research suggests that infliximab may cross the blood-brain barrier more effectively during active inflammation. By neutralizing excess TNF-α, the drug limits the vasculitis and exudative processes typical of TBM. Furthermore, it helps manage paradoxical reactions, which often occur when the immune system overreacts to dying mycobacteria. Clinicians should consider this approach for patients who show progressive neurological deficits despite receiving adequate antitubercular drugs and steroids.

Frequently Asked Questions

How does infliximab help in TBM?

Infliximab targets TNF-α, a cytokine that causes excessive inflammation in the brain during tuberculosis. By reducing this inflammation, the drug prevents further tissue damage and helps resolve neurological deficits that steroids may not adequately treat.

Is it safe to use a TNF-alpha inhibitor during an active infection?

While TNF-alpha inhibitors generally increase the risk of TB reactivation, they are used in these specific cases alongside effective antitubercular drugs. This combination allows the drugs to kill the bacteria while infliximab controls the host's dangerous inflammatory response.

When should clinicians consider infliximab for TBM?

Clinicians should consider infliximab for cases of TBM that are refractory to standard therapy or those involving severe paradoxical reactions that do not respond to high-dose corticosteroids.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Barone C et al. Infliximab in a Child With Relapsing Tuberculous Meningoencephalitis: A Case Report and Literature Review. Pediatr Infect Dis J. 2026 May 04. doi: 10.1097/INF.0000000000005253. PMID: 42081272.

Abo YN et al. Successful Treatment of a Severe Vision-Threatening Paradoxical Tuberculous Reaction with Infliximab: First Pediatric Use. Pediatr Infect Dis J. 2020 Apr;39(4):e42-e45. doi: 10.1097/INF.0000000000002578.

Eshagh D et al. Infliximab use for corticosteroid-resistant tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in an immunocompetent patient. Infection. 2020 Oct;48(5):799-802. doi: 10.1007/s15010-020-01433-z.